{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=11",
    "query": {
      "intervention": "bispecific antibody",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 362,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T02:38:07.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07405476",
      "title": "Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Carcinoma",
        "Colorectal Carcinoma",
        "Rectal Carcinoma",
        "Stage I Colon Cancer AJCC v8",
        "Stage I Colorectal Cancer AJCC v8",
        "Stage I Rectal Cancer AJCC v8",
        "Stage II Colon Cancer AJCC v8",
        "Stage II Colorectal Cancer AJCC v8",
        "Stage II Rectal Cancer AJCC v8",
        "Stage III Colon Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Rectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Zanidatamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Endoscopic Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Digital Rectal Examination",
          "type": "PROCEDURE"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2026-04-07",
      "completion_date": "2029-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Decatur, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07405476"
    },
    {
      "nct_id": "NCT06095089",
      "title": "A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "JNJ-78278343",
          "type": "DRUG"
        },
        {
          "name": "JNJ-87189401",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Lutetium Lu-177 Vipivotide Tetraxetan",
          "type": "DRUG"
        },
        {
          "name": "JNJ-101556143",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 355,
      "start_date": "2023-11-01",
      "completion_date": "2028-06-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06095089"
    },
    {
      "nct_id": "NCT07502872",
      "title": "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Lymphoma",
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "Tafasitamab",
          "type": "DRUG"
        },
        {
          "name": "Polatuzumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-11-01",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07502872"
    },
    {
      "nct_id": "NCT06510491",
      "title": "Epcoritamab in Previously Treated WM",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Waldenstrom Macroglobulinemia",
        "B-Cell Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Epcoritamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gottfried von Keudell, MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-12-06",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06510491"
    },
    {
      "nct_id": "NCT05123482",
      "title": "A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Biliary Tract Carcinoma",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Squamous Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AZD8205",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 and AZD2936 (Rilvegostomig)",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 and AZD5305 (saruparib)",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 in combination with AZD9574",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 460,
      "start_date": "2021-10-18",
      "completion_date": "2027-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123482"
    },
    {
      "nct_id": "NCT07700979",
      "title": "Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric / Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cadonilimab",
          "type": "DRUG"
        },
        {
          "name": "CAPOX regimen",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akeso",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2026-09-24",
      "completion_date": "2030-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07700979"
    },
    {
      "nct_id": "NCT07363408",
      "title": "Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Microsatellite Stable Colorectal Carcinoma",
        "Metastatic Microsatellite Stable Colorectal Carcinoma",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Muzastotug",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-12-01",
      "completion_date": "2027-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07363408"
    },
    {
      "nct_id": "NCT00522457",
      "title": "Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ertumaxomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neovii Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2008-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2011-04-29",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • Lebanon, New Hampshire • New York, New York",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00522457"
    },
    {
      "nct_id": "NCT05585034",
      "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma Excluding Uveal Melanoma",
        "Non-small Cell Lung Cancer, Squamous or Non-squamous",
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma, Clear Cell",
        "Castration-resistant Prostate Cancer",
        "Ovarian Cancer, Epithelial",
        "TNBC - Triple-Negative Breast Cancer",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "XmAb®808",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Keytruda® (pembrolizumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-12-14",
      "completion_date": "2025-05-20",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05585034"
    },
    {
      "nct_id": "NCT07227584",
      "title": "ALL Backbone in AYAs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome-Negative Lymphoblastic Leukemia",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        },
        {
          "name": "Oncaspar",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "ALL",
        "summary": "18 Years to 51 Years"
      },
      "enrollment_count": 67,
      "start_date": "2026-04-03",
      "completion_date": "2035-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-18T02:38:07.868Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227584"
    }
  ]
}